Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE promotes drug development with Joint Venture in China – first sales revenues of EUR 120.000 generated
DGAP-News: Aladdin Healthcare Technologies SE
/ Key word(s): Joint Venture
Aladdin Healthcare Technologies SE promotes drug development with Joint Venture in China – first sales revenues of EUR 120.000 generated Aladdin Healthcare Technologies SE promotes the use of artificial intelligence (AI) and knowledge databases in healthcare diagnostics. For this purpose, the company has founded Aladdin Healthcare Technologies Co. Ltd, China, with a network of scientists, pharmacologists and healthcare practitioners. Aladdin holds a 51% stake in the joint venture (JV). The company also succeeded in winning a new customer and generating initial sales revenues of EUR 120,000. The aim of the joint venture is to further develop and distribute AI-supported drug tools on a global scale. More specifically, this involves a knowledge database that uses artificial intelligence to make basic clinical research for the development of new drugs far more efficient. The tool enables the usual preclinical research period for new drugs to be shortened from 2 to 4 years to 8 to 12 months. With this tool, Aladdin primarily addresses age-related diseases such as Alzheimer’s disease, cardiovascular diseases, pulmonary diseases, diabetes and age-related osteoporosis. First achievements underline the high performance of intelligent databases. In the field of mitophagy, the tool identified seven potential hit compounds for the treatment of dementia, and four further hit compounds deal with age-related osteoporosis. In cell tests, two more compounds show nanomolar bioactivity and low toxicity. These results provide valid basis for producing highly effective drugs. Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, says: “The use of Artificial Intelligence in medicine is a great promise for the future. It will support research-based pharmaceutical companies in the development of new drugs, make clinical diagnostics more efficient and pool medical knowledge. At Aladdin, we are working on this technological advance that benefits everyone and always aims to improve the lives of patients.” About Aladdin Healthcare Technologies SE For further information Contact Press
30.04.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Aladdin Healthcare Technologies SE |
Unter den Linden 10 | |
10117 Berlin | |
Germany | |
Phone: | 030 700140449 |
E-mail: | info@aladdinid.com |
Internet: | www.aladdinid.com |
ISIN: | DE000A12ULL2 |
WKN: | A12ULL |
Listed: | Regulated Market in Dusseldorf |
EQS News ID: | 1033185 |
End of News | DGAP News Service |